Egenesis Stock

egenesisbio.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $428.86MM

eGenesis is a biotechnology company which offers xenotransplantation technologies to patients with life-threatening conditions. This company was founded by George Church Ph.D and Luhan Yang Ph.D in 2015 and is headquartered in Cambridge, MA. eGenesis uses advanced gene-editing techniques, including CRISPR, to engineer animal organs intended for transplantation into human patients, aiming to provide a sustainable source of organs and tissues.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Egenesis, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation
Private Market Pricing DetailsValuation & Financings

Enterprise Value

Powered by Forge Data

Access Egenesis’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Animation displayed is not current and securities are shown for illustrative purposes only.

Egenesis Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Egenesis Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Egenesis investors also invested in these private companies

Altium Capital
Eisai Innovation
DaVita
Heritage Provider Network
Fan Ventures
Lifesci Venture Partners
Biomatics Capital
Berggruen Holdings North America
NATCO Pharmaceuticals
Fresenius Medical Care Ventures
Wellington Partners

Leadership & Board

Leadership

Michael Curtis Ph.D
President & Chief Executive Officer
Jennifer Bergheiser
Chief Business Officer
Elizabeth Roberts
Chief People Officer
Susan Low Ph.D
Head of Development
Kathryn Stiede
Head of Clinical Operations
Wenning Qin Ph.D
Senior Vice President of Innovation

Board

Steven Gillis Ph.D
ARCH Venture Partners
Lucio Iannone Ph.D
Leaps by Bayer

Egenesis stock FAQs

plusminus

Can you buy Egenesis stock?

As Egenesis is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Egenesis, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Egenesis stock?

To invest in a private company like Egenesis through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Egenesis stock?

Yes, you may sell the Egenesis stock you currently own. Forge can help you facilitates the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Egenesis stock?

If you hold private company shares of Egenesis – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Egenesis on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Egenesis a public company?

No, Egenesis is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is stock price?

Egenesis is a privately held company and therefore does not have a public stock price. However, you may access Egenesis private market stock price with Forge Data.
plusminus

What is stock ticker symbol?

Egenesis does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Egenesis’ news and media highlights

eGenesis, a developer of human-compatible organs that are derived from pigs, raised $191 million in new venture capital funding. There are over 100,000 people in the U.S. on organ transplant waiting lists, the vast majority of whom are in need of kidneys. eGenesis provided the genetically-edited porcine kidney used earlier this year in a landmark human transplant, and is working with the FDA to move into Phase 1 clinical trials.
Last Thursday, surgeons at Massachusetts General Hospital announced that for the first time, a living human patient had received a kidney transplant from a pig. This scientific breakthrough represents hope for the dozens of people who die every day waiting on an organ transplant, the hospital’s transplant director Joren Madsen said at a press conference following the announcement. Of course, it wasn’t as simple as just going down to the farm. The kidney was developed by Massachusetts-based startup eGenesis, which has been working on gene-editing porcine organs so that they can be safely transplanted into humans for nearly a decade.
eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and OrganOx, a medical device company with a focus on the therapeutic applications of isolated organ perfusion, today announced the successful completion of an extracorporeal perfusion of a brain-dead research donor using a genetically engineered porcine liver. The donor was the first to be enrolled in the ongoing PERFUSE-2 study.
eGenesis, a biotechnology company, has presented preclinical data on genetically engineered porcine kidneys demonstrating recipient survival and compatibility. The data was presented at the 2023 IPITA-IXA-CTRMS Joint Conference. The company is aiming to develop human-compatible organs for organ transplant, addressing the shortage of organs available for transplant.
Updated on: Oct 6, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price™ may rely on a very limited number of inputs in its calculation. Forge Price™ is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price™, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price™. Forge Price™ is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price™ is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price™ for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.